8-K: Dogwood Therapeutics Advances Cancer Pain Treatments

Dogwood Therapeutics provides a Q4 2025 update, highlighting progress in its Halneuron and SP16 programs for cancer-related neuropathy and pain.

Summary

• Dogwood Therapeutics, Inc. (DWTX) is focused on developing first-in-class therapeutic treatments for cancer patients suffering from neuropathy, with a goal to expand into general cancer pain and acute surgical pain.
• The company's lead candidate, Halneuron (Tetrodotoxin or TTX), is a Nav1.7 channel blocker in Phase 2b development for Chemotherapy-Induced Peripheral Neuropathy (CINP).
• Halneuron demonstrated statistically significant efficacy in a previous Phase 2 Cancer Related Pain (CRP) study, with 51% of patients experiencing a 30% reduction in pain versus 35% on placebo (p=0.046).
• Responders to Halneuron in the CRP study experienced pain relief for an average of 57.7 days post-injection, compared to 10.5 days for placebo responders.
• A Phase 2a signal-seeking study for CINP identified 30 ug once daily (QD) as the optimal dose for Phase 2b, showing comparable efficacy to twice daily (BID) dosing with a superior adverse event profile.
• The ongoing Halneuron Phase 2b CINP study has randomized over 80 patients, with 60 having completed treatment, targeting a total enrollment of 200 patients.
• SP16, an LRP1-agonist, is an early clinical stage program for the attenuation of CIPN during chemotherapy, with preclinical data suggesting anti-inflammatory and neuroprotective effects.
• SP16 research is funded by the National Cancer Institute (NCI) and will be executed at the University of Virginia, with an IND filed in Q4 2025 to advance to a Phase 1b safety study.
• The CINP drug market is estimated at approximately $1.9 billion, with the broader cancer pain market at $6 billion and the global pain management drug market at $35 billion.
• Upon shareholder approval for the conversion of existing Preferred Stock, there will be approximately 30 million common shares outstanding on a fully diluted basis.
• CK Life Sciences Intl. (CKLS) and Serpin Pharma, Inc. (Serpin Pharma) are expected to own approximately 83% and 7% of DWTX stock, respectively, post-conversion.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, emphasizing significant progress in clinical trials for both Halneuron and SP16, strong preclinical data, large market opportunities, and NCI funding for one of its programs. The statistically significant results and long duration of pain relief for Halneuron are particularly strong positives. The only minor detraction is the general forward-looking statement disclaimer, which is standard.

Positives

• Halneuron demonstrated statistically significant pain reduction in a Phase 2 CRP study (p=0.046), with 51% responders compared to 35% for placebo.
• Halneuron responders experienced a long duration of pain relief, averaging 57.7 days, which is significantly longer than placebo responders (10.5 days).
• Preclinical efficacy of Halneuron in rat models of neuropathic pain compares favorably with recently approved Suzetrigine at significantly lower doses.
• Halneuron is selective for the Nav 1.7 channel in peripheral tissues, minimizing central nervous system adverse events and cardiac impact.
• SP16 preclinical research shows analgesic effects, inhibition of pain responses and inflammation, and potential to prevent and/or repair nerve damage associated with chemotherapy.
• In-vitro assays indicate SP16 does not appear to interfere with the effectiveness of common chemotherapy regimes.
• The SP16 program is fully funded by the NCI through its next clinical milestone, reducing financial burden on the company.
• The company's executive team possesses extensive drug development and commercialization experience.
• Significant market opportunities exist in CINP ($1.9B), cancer pain ($6B), and global pain management ($35B), with chemotherapy utilization projected to increase by 54% by 2040.

Risks

• Inherent uncertainties, risks, and assumptions are difficult to predict, including those related to the completion, timing, and results of current and future clinical studies for product candidates.
• Forward-looking statements are based on assumptions about future events that may not prove to be accurate.
• Risks and uncertainties are described more fully in the Risk Factors section of the Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company anticipates significant progress in its Halneuron and SP16 clinical programs, with key milestones including interim data readout for Halneuron's Phase 2b CINP study and patient enrollment for SP16's Phase 1b CIPN study in the near future. They also expect to file new synthetic Halneuron IP and potentially secure FDA Fast Track Designation for Halneuron. The long-term outlook includes expanding Halneuron's utility to general cancer pain and acute surgical pain, and leveraging SP16's neuroprotective capabilities to complement Halneuron in treating post-chemotherapy pain, aiming for deeper penetration into the global CINP and broader cancer pain markets.

Management Comments

• Dogwood is deeply committed to advancing first-in-class new therapeutic treatments for cancer patients suffering from neuropathy, with the goal to expand to reducing general cancer pain and acute surgical pain.
• Halneuron represents a logical approach that we believe fulfills many requirements of an ideal analgesic.
• Halneuron's Nav 1.7 inhibition mechanism is supported by real-world patient experience.
• SP16 may enable neuroprotection, preserve full chemo regimen, and has the potential to synergistically complement Halneuron in treating pain post chemotherapy.

Industry Context

The company operates within the rapidly evolving pain management and oncology sectors, specifically addressing the significant unmet medical need of Chemotherapy-Induced Peripheral Neuropathy (CINP). With chemotherapy utilization projected to increase substantially by 2040, the incidence of CINP is also expected to rise. The market is currently dominated by opioids and other less effective treatments, which often come with severe side effects and addiction risks. Dogwood's focus on non-opioid, targeted therapies like Halneuron (Nav1.7 blocker) and SP16 (LRP1-agonist, neuroprotection) positions it to capitalize on the growing demand for safer and more effective pain management solutions, particularly in the context of the ongoing opioid crisis. The NCI funding for SP16 underscores the recognized need for novel CIPN treatments.

Comparison to Industry Standards

• Halneuron's efficacy in preclinical paw withdrawal models compares favorably with recently approved Suzetrigine at all tested doses, with Halneuron using 1000X lower doses than VX548 (another TTX compound).
• The company highlights that current CINP treatments often involve medications like duloxetine, gabapentin, pregabalin, tricyclic antidepressants, and opioids, with opioids accounting for 38%-58% of CINP treatment depending on the market.
• Halneuron's therapeutic profile, including Nav 1.7 inhibition, is presented as fulfilling many requirements of an ideal analgesic, suggesting an improvement over existing options.

Corporate Governance

Related Party Transactions

• CK Life Sciences Intl., (Holdings) Inc. (CKLS) owns approximately 2,108 shares of Series A and approximately 284 shares of Series A-1 Preferred Stock.
• Serpin Pharma, Inc. (Serpin Pharma) owns approximately 179 Series A-2 Preferred Stock.
• Upon conversion of the existing Preferred Stock into common stock following shareholder approval, CKLS is expected to own approximately 83% and Serpin Pharma approximately 7% of DWTX stock, totaling approximately 90% for the two largest shareholders.

Stakeholder Impact

• Shareholders: The expected special meeting for preferred stock conversion and business combination with Wex Pharmaceuticals, Inc. will significantly impact the capital structure and potentially the valuation of common shares. Existing common shareholders will see dilution from the conversion of preferred stock.
• Patients: The advancement of Halneuron and SP16 programs offers potential new, non-opioid therapeutic options for cancer patients suffering from neuropathy, addressing a major unmet medical need and improving quality of life.
• Investment Professionals/Analysts: The detailed clinical data, market opportunity analysis, and future milestones provide critical information for evaluating the company's investment potential.
• Regulatory Authorities: The company's engagement with the FDA for Fast Track Designation and IND filings indicates adherence to regulatory pathways for drug development.

Next Steps

• Dr. Gendreau to present Halneuron Program Overview at the 19th Annual Pain Summit in San Diego, CA on October 14, 2025.
• Recruitment of 100 patients in the Halneuron Phase 2b study by Q4 2025.
• Filing of new synthetic Halneuron IP by Q4 2025.
• Halneuron Phase 2b interim data readout projected for Q4 2025.
• SP16 IND filed to advance to Phase 1b Safety Study in Q4 2025.
• Patient enrollment in SP16 Phase 1b CIPN Study in 1H 2026 (subject to FDA review).
• Final data for the 200-patient Halneuron Phase 2b CINP study in Q2/Q3 2026.
• Seek FDA Fast Track Designation for Halneuron for the treatment of CINP.

Key Dates

Recommendation

The filing presents compelling evidence of significant progress in Dogwood Therapeutics' clinical pipeline, particularly with Halneuron showing statistically significant efficacy and long-duration pain relief in Phase 2 studies for cancer-related pain. The large and growing market for CINP and broader cancer pain, coupled with the company's focus on non-opioid solutions, positions it favorably. The NCI funding for the SP16 program further de-risks its development. Upcoming catalysts like the Halneuron Phase 2b interim data readout and potential FDA Fast Track Designation are likely to drive significant share price appreciation. While shareholder approval for preferred stock conversion and the business combination are pending, the underlying clinical data and market opportunity suggest a strong growth trajectory for the company.

Keywords

Chemotherapy-Induced Peripheral Neuropathy, CINP, Cancer Pain, Neuropathy, Halneuron, Tetrodotoxin, TTX, Nav1.7 channel blocker, SP16, LRP1-agonist, Pain Management, Oncology, Drug Development, Clinical Trials, Biotechnology, Pharmaceuticals